secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001193125-25-065564
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion CEO Thomas Butler out; Board member Mick Hitchcock named interim CEO
--------------------------------------------------------------------------------

- Thomas Butler terminated as CEO, resigned as director and Chairman effective March 25, 2025.
- Michael J.M. Hitchcock (Mick) appointed interim CEO; Rainer Erdtmann named principal financial officer.
- Audit Committee now has only two members due to Hitchcock's resignation; Nasdaq cure period until March 25, 2026.
- Hitchcock receives $633,000 base salary, 50% target bonus, and options for 350,000 shares at $2.52/share.
- Press release cites positive Phase II data for icovamenib as company pursues diabetes therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/0001193125-25-065564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/d945354d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-065564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer